news
Tract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
List view / Grid view
Oncology
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
article
Why DNA Damage Response deserves renewed focus in cancer therapy
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and…
news
Novel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
news
New research offers hope for high-grade glioma treatment
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
news
Nanoparticle therapy shows potential to prevent spread of pancreatic cancer to liver
Pancreatic cancer is notoriously hard to treat, especially when it spreads to the liver in advanced stages. Researchers at UCLA’s California NanoSystems Institute (CNSI) have developed an innovative nanoparticle technology to tackle this challenge.
news
Beckman Coulter Life Sciences and Rarity Bioscience partner to advance oncology research
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
news
Diabetes drug found to protect heart during cancer treatment
A commonly prescribed diabetes medication could significantly enhance long-term recovery prospects for cancer patients by reducing their risk of heart failure, a new study from the University of East Anglia (UEA) reveals.
news
FORESIGHT consortium secures €9 million to fast-track drug development
The FORESIGHT consortium has secured €9 million to speed up drug development using advanced molecular imaging, targeting major diseases like cancer, autoimmune conditions, and heart disorders.
article
New cell therapy model accelerates cancer treatment development
CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, more efficient cell therapy development - learn how they’re doing it.
news
New CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
article
Biotech leader champions targeted cancer treatments and diversity
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
news
INPP4B exerts its tumour-promoting effects via lysosomes
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
news
p53’s role in ulcerative colitis and its progression to cancer
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
whitepaper
Beyond the lab: antibodies
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
news
How chronic stress hastens the progression of colorectal cancer
A new study, presented at the United European Gastroenterology, reveals how chronic stress disturbs the balance of gut microbiota and influences CRC progression.
